Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.43 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.40 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749532 | 0.89 | MCHR1 (0.42) | MCHR1LGMNNOTUMMAP4K4IP6K1 | |
| SCHEMBL1749372 | 0.86 | NOTUM (0.44) | MCHR1NOTUMSETD2MAP4K4NSD2 | |
| SCHEMBL1750696 | 0.86 | NOTUM (0.44) | MCHR1NOTUMSETD2MAP4K4NSD2 | |
| SCHEMBL1749590 | 0.84 | NOTUM (0.51) | MCHR1NOTUMCHRM4 | |
| SCHEMBL1750140 | 0.84 | GAA (0.49) | GAARAD52MCHR1MAP4K4 | |
| SCHEMBL4299094 | 0.84 | GAA (0.49) | GAARAD52MCHR1MAP4K4 | |
| SCHEMBL4253950 | 0.84 | GAA (0.49) | GAARAD52MCHR1MAP4K4 | |
| SCHEMBL6792109 | 0.83 | AR (0.41) | MCHR1LGMNNOTUMMAP4K4CHRM4 | |
| SCHEMBL1749695 | 0.83 | MCHR1 (0.49) | MCHR1NOTUMMAP4K4CHRM4 | |
| SCHEMBL2637307 | 0.83 | MCHR1 (0.49) | MCHR1NOTUMMAP4K4CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | GAA 1379/4885RAD52 4243/4885MCHR1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.